Nesline, M.K.; Previs, R.A.; Dy, G.K.; Deng, L.; Lee, Y.H.; DePietro, P.; Zhang, S.; Meyers, N.; Severson, E.; Ramkissoon, S.;
et al. PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. Cancers 2023, 15, 4789.
https://doi.org/10.3390/cancers15194789
AMA Style
Nesline MK, Previs RA, Dy GK, Deng L, Lee YH, DePietro P, Zhang S, Meyers N, Severson E, Ramkissoon S,
et al. PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. Cancers. 2023; 15(19):4789.
https://doi.org/10.3390/cancers15194789
Chicago/Turabian Style
Nesline, Mary K., Rebecca A. Previs, Grace K. Dy, Lei Deng, Yong Hee Lee, Paul DePietro, Shengle Zhang, Nathan Meyers, Eric Severson, Shakti Ramkissoon,
and et al. 2023. "PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes" Cancers 15, no. 19: 4789.
https://doi.org/10.3390/cancers15194789
APA Style
Nesline, M. K., Previs, R. A., Dy, G. K., Deng, L., Lee, Y. H., DePietro, P., Zhang, S., Meyers, N., Severson, E., Ramkissoon, S., Pabla, S., & Conroy, J. M.
(2023). PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. Cancers, 15(19), 4789.
https://doi.org/10.3390/cancers15194789
